AQSZF- wrong key data, wrong sector and industry
Sector Health Care
Aequus Pharmaceuticals Inc., a specialty pharmaceutical company, develops and commercializes drugs in Canada. It focuses on various therapeutic areas, including neurology, ophthalmology, and transplantation. The company markets Tacrolimus IR, an immunosuppressant for the treatment and prevention of acute rejection following organ transplantation; Vistitan, an ophthalmology product to reduce elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Zepto, a precision pulse capsulotomy system that provides anterior lens capsulotomies during cataract surgeries; and Topiramate and Oxcarbazepine extended-release tablets for the treatment of epilepsy. Its development stage product candidates include AQS1301, a transdermal formulation of aripiprazole for the treatment of bipolar I disorders, schizophrenia, and irritability associated with autistic disorders, as well as depressive disorders; AQS1303, a transdermal pyridoxine/ doxylamine for the treatment of nausea and vomiting of pregnancy; and AQS1304 to treat neurological disorders. The company has a collaboration agreement with Scientus Pharma Inc. for the development and commercial supply of specific cannabinoid extracts; and licensing agreement with Supernus Pharmaceuticals, Inc. for the development and commercialization of products for the treatment of central nervous system disorders. Aequus Pharmaceuticals Inc. was founded in 2013 and is headquartered in Vancouver, Canada.